Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891696099> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2891696099 abstract "e20516 Background: Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting ALK, MET, and ROS1 tyrosine kinases. It was first approved by the Food and Drug Administration (FDA) in 2011 for treatment of patients in late-stage (locally advanced or metastatic) non-small cell lung cancer (NSCLC) with abnormal anaplastic lymphoma kinase (ALK) gene as detected by an FDA-approved test, as it confers improved progression-free survival comparison with chemotherapy. Methods: This is a retrospective chart review study of patients with stage IV ALK-positive NSCLC who attended the medical oncology department of Kuwait Cancer Control Centre (Kuwait) and King Fahad Specialist Hospital (Saudi Arabia) between January 2013 and May 2016. The efficacy and safety of crizotinib (250 mg orally, twice daily, with or without food.) were evaluated based on overall survival (OS), progression-free survival (PFS), Objective response rate (ORR), time to objective response, duration of response, and dose reduction or cessation because of crizotinib toxicity. Results: Twenty-three patients were involved in this study with a median age of 55.5 years and male-to-female ratio of 2.4:1 The median OS from initiation of crizotinib has not been reached; 1-year overall survival was 71.2%. Crizotinib treatment demonstrated median PFS of 9.6 months (95% CI, 3.0-24.1 months). The ORR was 70.9%. Complete response was achieved in 4.2% of patients, and partial response was achieved in 66.7% of patients. The most frequently reported adverse effects of crizotinib (Grade 1 / 2) were muscle ache, fatigue, nausea, vomiting, diarrhea, constipation, edema, elevated transaminases, bradycardia, and vision disorders. Grade 3 / 4 diarrhea was reported in 12.5% of patients. The proportion of patients who required dose reduction because of Crizotinib-induced bradycardia was 8.3% of patients. Conclusions: Crizotinib appears to be a very favorable option for treating patients with stage IV ALK-positive NSCLC. Crizotinib showed a very tolerable toxicity profile." @default.
- W2891696099 created "2018-09-27" @default.
- W2891696099 creator A5011358585 @default.
- W2891696099 creator A5031893524 @default.
- W2891696099 date "2017-05-20" @default.
- W2891696099 modified "2023-09-23" @default.
- W2891696099 title "Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive stage IV non-small cell lung cancer." @default.
- W2891696099 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20516" @default.
- W2891696099 hasPublicationYear "2017" @default.
- W2891696099 type Work @default.
- W2891696099 sameAs 2891696099 @default.
- W2891696099 citedByCount "2" @default.
- W2891696099 countsByYear W28916960992018 @default.
- W2891696099 countsByYear W28916960992020 @default.
- W2891696099 crossrefType "journal-article" @default.
- W2891696099 hasAuthorship W2891696099A5011358585 @default.
- W2891696099 hasAuthorship W2891696099A5031893524 @default.
- W2891696099 hasConcept C117643217 @default.
- W2891696099 hasConcept C126322002 @default.
- W2891696099 hasConcept C143998085 @default.
- W2891696099 hasConcept C146357865 @default.
- W2891696099 hasConcept C151730666 @default.
- W2891696099 hasConcept C2776232967 @default.
- W2891696099 hasConcept C2776256026 @default.
- W2891696099 hasConcept C2778347629 @default.
- W2891696099 hasConcept C2779338263 @default.
- W2891696099 hasConcept C2779422266 @default.
- W2891696099 hasConcept C502942594 @default.
- W2891696099 hasConcept C71924100 @default.
- W2891696099 hasConcept C86803240 @default.
- W2891696099 hasConceptScore W2891696099C117643217 @default.
- W2891696099 hasConceptScore W2891696099C126322002 @default.
- W2891696099 hasConceptScore W2891696099C143998085 @default.
- W2891696099 hasConceptScore W2891696099C146357865 @default.
- W2891696099 hasConceptScore W2891696099C151730666 @default.
- W2891696099 hasConceptScore W2891696099C2776232967 @default.
- W2891696099 hasConceptScore W2891696099C2776256026 @default.
- W2891696099 hasConceptScore W2891696099C2778347629 @default.
- W2891696099 hasConceptScore W2891696099C2779338263 @default.
- W2891696099 hasConceptScore W2891696099C2779422266 @default.
- W2891696099 hasConceptScore W2891696099C502942594 @default.
- W2891696099 hasConceptScore W2891696099C71924100 @default.
- W2891696099 hasConceptScore W2891696099C86803240 @default.
- W2891696099 hasLocation W28916960991 @default.
- W2891696099 hasOpenAccess W2891696099 @default.
- W2891696099 hasPrimaryLocation W28916960991 @default.
- W2891696099 hasRelatedWork W103750898 @default.
- W2891696099 hasRelatedWork W1855533555 @default.
- W2891696099 hasRelatedWork W1897110694 @default.
- W2891696099 hasRelatedWork W1992447906 @default.
- W2891696099 hasRelatedWork W2015861437 @default.
- W2891696099 hasRelatedWork W2043537675 @default.
- W2891696099 hasRelatedWork W2062272737 @default.
- W2891696099 hasRelatedWork W2106706414 @default.
- W2891696099 hasRelatedWork W2156486640 @default.
- W2891696099 hasRelatedWork W2174680146 @default.
- W2891696099 hasRelatedWork W2311424771 @default.
- W2891696099 hasRelatedWork W2337452654 @default.
- W2891696099 hasRelatedWork W2463167950 @default.
- W2891696099 hasRelatedWork W2493360131 @default.
- W2891696099 hasRelatedWork W2593114305 @default.
- W2891696099 hasRelatedWork W2753977688 @default.
- W2891696099 hasRelatedWork W2767655639 @default.
- W2891696099 hasRelatedWork W2772410896 @default.
- W2891696099 hasRelatedWork W2940933294 @default.
- W2891696099 hasRelatedWork W67737930 @default.
- W2891696099 isParatext "false" @default.
- W2891696099 isRetracted "false" @default.
- W2891696099 magId "2891696099" @default.
- W2891696099 workType "article" @default.